Regeneron Secures FDA Priority Review for Cemdisiran in gMG

Regeneron Pharmaceuticals has secured regulatory acceptance of applications for cemdisiran, an investigational therapy for adults with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG). The U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) under Priority Review and assigned a target action date in November 2026. Priority Review shortens the FDA review timeline to approximately six months compared with the standard ten-month review period. The European Medicines Agency (EMA) has also validated the marketing application, confirming that the submission is complete and allowing formal scientific review to begin. A European Commission decision is expected in the second half of 2027.

If approved, cemdisiran could become the first small interfering RNA (siRNA) therapy available for gMG and the only treatment in the disease administered as a subcutaneous injection once every 12 weeks.

Targeting the Complement Pathway Through RNA Interference

Cemdisiran uses RNA interference technology to suppress production of complement component C5, a key driver of immune-mediated damage in myasthenia gravis. In patients with anti-AChR-positive disease, autoantibodies activate the complement system, leading to destruction of the neuromuscular junction and impaired communication between nerves and muscles.

Generalized myasthenia gravis is a chronic autoimmune disorder characterized by fluctuating muscle weakness, fatigue, impaired mobility, and difficulties with speech and swallowing. Although several targeted therapies have emerged in recent years, many patients continue to require long-term immunosuppressive treatment and experience incomplete disease control. Current complement inhibitors often require biweekly or monthly administration, creating an ongoing treatment burden for many patients.

Phase 3 NIMBLE Trial Supported Regulatory Filings

The regulatory submissions are supported by results from the Phase 3 NIMBLE study (NCT05070858), one of the largest global interventional trials conducted in generalized myasthenia gravis. The trial evaluated cemdisiran in adults with symptomatic gMG, including patients receiving background immunosuppressive therapies at the investigator’s discretion.

Participants received subcutaneous cemdisiran every 12 weeks, providing a substantially less frequent dosing schedule than many currently available targeted therapies. Full Phase 3 findings were published in The Lancet and presented at the 2026 American Academy of Neurology Annual Meeting.

While Regeneron did not disclose additional efficacy results in its regulatory update, previously reported NIMBLE data supported advancement to regulatory review based on clinically meaningful improvements in disease activity and an acceptable safety profile. The safety findings were consistent with the known effects of complement inhibition, with no unexpected safety signals reported during the study.

Strategic Milestone for Regeneron’s RNA-Based Medicine Portfolio

The filing marks an important step in Regeneron’s expansion beyond antibody therapeutics into RNA-based medicines. Cemdisiran is being developed under a worldwide licensing agreement with Alnylam Pharmaceuticals, with Regeneron responsible for global development, manufacturing, and commercialization of the therapy as both a monotherapy and in combination with C5-targeting antibodies.

Company leadership emphasized the potential value of combining targeted complement suppression with infrequent subcutaneous administration, a profile that may help reduce treatment burden for patients requiring long-term disease management.

Clinical Path Forward

The FDA is expected to deliver its review decision in November 2026 under the Priority Review pathway. In Europe, a regulatory decision is anticipated during the second half of 2027. Regeneron also plans to submit a regulatory application in Japan in early 2027, further expanding cemdisiran’s global regulatory pathway.

If approved across major markets, cemdisiran could introduce the first RNA interference-based treatment for generalized myasthenia gravis and provide patients with a quarterly dosing option that differs from existing complement-targeted therapies.

What This Means for Patients

Generalized myasthenia gravis (gMG) is a chronic autoimmune condition that causes muscle weakness, fatigue, difficulty speaking, swallowing challenges, and limitations in daily activities. Many patients require ongoing therapy and may continue to experience symptoms despite currently available treatments.

Cemdisiran is still investigational and has not yet been approved. If regulators grant approval, it could provide a new option administered as a subcutaneous injection only once every 12 weeks just four times a year. This extended dosing interval may ease the treatment burden compared with therapies that require more frequent infusions or injections. The FDA is expected to issue its review decision in November 2026.

Reference

Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG) | Regeneron Pharmaceuticals Inc.